With a forward P/E ratio of 5.79 and a PEG ratio of 0.05, BioNTech played a huge part in formulating the BioNTech-Pfizer vaccine ... supplies ferro-alloys; along with processes ferrous and ...

Big pharma's interest in using protein degradation as a therapeutic strategy continues with a wide-ranging deal between Pfizer and US biotech Triana Biomedicines that could be worth $1.5 billion ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug classes in oncology, via a $6 billion licensing deal with China's 3SBio.